Related Experiment Video
Updated: Aug 25, 2025
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia
Xueqian Li1,2, Jiaqian Qi1,2,3, Xiaofei Song1,2
1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu, People's Republic of China.
Insights
This study identified DLC1 as a potential prognostic marker for Acute Myeloid Leukemia (AML). Low DLC1 levels are associated with poorer long-term outcomes in AML patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute Myeloid Leukemia (AML) is a complex hematologic malignancy with many genes of unclear prognostic significance.
- Identifying novel prognostic markers is crucial for improving patient outcomes in AML.
Discussion:
- This study utilized WGCNA, LASSO, and SVM-RFE to screen five candidate genes (DLC1, NF1B, DENND5B, TANC2, ELAVL4) from large-scale genomic data.
- Survival analysis in the TCGA database and external validation revealed DLC1 as a significant prognostic factor.
Key Insights:
- Low expression of DLC1 is linked to unfavorable long-term prognosis in Acute Myeloid Leukemia patients.
- DLC1 emerges as a potential predictive biomarker for AML prognosis.
Outlook:
- Further research into the functional role of DLC1 in AML pathogenesis is warranted.
- DLC1 could be a target for novel therapeutic strategies aimed at improving AML patient survival.
Abstract:
Acute myeloid leukemia (AML) is a complex, heterogeneous malignant hematologic disease. Although multiple prognostic-related genes gave been explored in previous studies, there are still many genes whose prognostic value remains unclear. In this study, a total of 1532 AML patients from three GEO databases were included, five genes with potential prognostic value (DLC1, NF1B, DENND5B, TANC2 and ELAVL4) were screened by weighted gene co-expression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO) and support vector machine recursive feature elimination (SVM-RFE). Based on this, we conducted survival analysis of the above five genes through the TCGA database and found that low level of DLC1 was detrimental to the long-term prognosis of AML patients. We also performed external validation in 48 AML patients from our medical center to analyze the impact of DLC1 level on prognosis. In conclusion, DLC1 may be a potential marker affecting the prognosis of AML, and its deficiency is associated with poor prognosis.
More Related Videos
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018